Evolution of Indications for Liver Transplantation (LTx) in the Years 2001-2017 in Poland.


Journal

Annals of transplantation
ISSN: 2329-0358
Titre abrégé: Ann Transplant
Pays: United States
ID NLM: 9802544

Informations de publication

Date de publication:
31 May 2019
Historique:
entrez: 1 6 2019
pubmed: 31 5 2019
medline: 17 1 2020
Statut: epublish

Résumé

BACKGROUND Hepatitis B and C viruses have been recognized as undoubtedly carcinogenic to humans. In the Polish population, where most people are protected by HBV vaccinations, hepatocellular carcinoma (HCC) and its main cause, persistent HCV infection, significantly affect the demand for liver transplantations. MATERIAL AND METHODS The purpose of this study was to categorize the number of primary liver transplantations in Poland in the years 2001-2017 by cause and to analyze changes in LTx indications during this period. Data were sourced from POLTRANSPLANT, the Organization and Coordination Center for Transplantation in Poland. Additionally, we compared the numbers of HCC cases and hepatitis B and C cases during this period. RESULTS In the analyzed period, in Poland, 3332 primary liver transplantations were performed. Overall, 44% (1456) of LTx cases were combined with HBV and/or HCV and/or HCC. In this group, transplants in patients with only 1 specific factor - HCV - formed the largest cohort, accounting for about 40% (581) of cases. Transplants in patients who only had HBV and in those who only had HCC accounted for 12% (185) and 5% (69), respectively. CONCLUSIONS The analyzed data suggest that HCV infections are a significant public health problem in Poland, as is also reflected by the growing number of LTx performed due to HCC. To limit the numbers of HCV and HCC cases, immediate implementation of a Polish National Program against HCV should be considered.

Identifiants

pubmed: 31147531
pii: 915958
doi: 10.12659/AOT.915958
pmc: PMC6561144
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

312-318

Références

Gastroenterology. 2012 May;142(6):1373-1383.e1
pubmed: 22537446
Cold Spring Harb Perspect Med. 2014 May 01;4(5):null
pubmed: 24789874
Eur J Gastroenterol Hepatol. 2015 Jan;27(1):70-6
pubmed: 25426979
Cancer Epidemiol. 2015 Dec;39 Suppl 1:S120-38
pubmed: 26589774
Wien Klin Wochenschr. 2016 Oct;128(19-20):679-690
pubmed: 27590261
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
Lancet Public Health. 2019 Jan;4(1):e19-e27
pubmed: 30291040

Auteurs

Paweł Koczkodaj (P)

Division of Teaching and Outcomes of Education, Medical University of Warsaw, Warsaw, Poland.
Department of Epidemiology and Cancer Prevention, Maria Skłodowska-Curie Institute Oncology Center, Warsaw, Poland.

Wojciech Straś (W)

Adamed Pharma, Commercial Operations Area, Warsaw, Poland.

Jarosław Czerwiński (J)

Departament of Emergency Medicine, First Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland.
Polish Transplant Coordinating Center POLTRANSPLANT, Warsaw, Poland.

Piotr Małkowski (P)

Department of Surgical and Transplantation Nursing and Extracorporeal Therapies, Medical University of Warsaw, Warsaw, Poland.

Mariusz Panczyk (M)

Division of Teaching and Outcomes of Education, Medical University of Warsaw, Warsaw, Poland.

Joanna Gotlib (J)

Division of Teaching and Outcomes of Education, Medical University of Warsaw, Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH